13 recruiting, 5 completed, 3 not yet recruiting, 2 unknown. 8 Phase 1, 7 Phase 2, 3 Not applicable, 2 Early Phase 1, 1 Phase 3.
Follow Solid Cancer: new trials by email Literature Review of Solid Cancer trials Research Report on Solid Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PRaG-1 Plus PRaG Therapy in in Elderly Patients With Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0) Adebrelimab - Solid Cancer, Lymphopenia | Phase 2 | Recruiting | Second Affiliated Hospital of Soochow University | 65 | 2026-08-10 | 2026-11-12 |
| A Study of SI-B036 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors SI-B036 - Urological Cancer, Solid Cancer | Phase 1 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 30 | 2026-08-01 | 2026-08-26 |
| Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors Urolithin A, Placebo, Bio specimens - Solid Cancer, Non-Small Cell Lung Cancer | Not applicable | Recruiting | Goethe University | 45 | 2026-01-02 | 2026-01-08 |
| TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors TC-G203 cells treatment - Solid Cancer, GPC3 Positive Hepatocellular Carcinoma | Early Phase 1 | Recruiting | Beijing GoBroad Hospital | 30 | 2025-12-18 | 2026-01-21 |
| Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors PRaG-1, Placebo - Solid Cancer, Lymphopenia | Phase 2 | Recruiting | Second Affiliated Hospital of Soochow University | 127 | 2025-12-01 | 2026-01-09 |
| A Study of AK138D1 in Advanced Malignant Tumors AK138D1 - Solid Cancer | Phase 1 | Recruiting | Akeso | 200 | 2025-10-22 | 2025-12-15 |
| Impact of Interventional Endoscopy on Quality of Life in Patients With Acute Respiratory Distress Due to Tumor Compression or Obstruction of the Lower Respiratory Tract bronchoscope - Solid Cancer, Bronchial Endoscopy | Not yet recruiting | University Hospital, Grenoble | 60 | 2025-08-01 | 2025-07-04 | |
| Immune Modulation With PRaG-1 Treatment PRaG-1(cordycepin tablet) - Cancer, Solid Cancer | Phase 2 | Not yet recruiting | Second Affiliated Hospital of Soochow University | 19 | 2025-06-15 | 2025-06-10 |
| Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Patients Receiving Oral Treatment for Cancer or Malignant Haemopathy (ACCELER PLATFORM) Decentralised Pathway Coordinated by the Advanced Practice Nurse - Solid Cancer, Haematological Malignancies | Not applicable | Recruiting | Institut Claudius Regaud | 33 | 2025-05-19 | 2026-09-02 |
| Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors HCB101, Trastuzumab, Pertuzumab - Solid Cancer | Phase 1 / Phase 2 | Active not recruiting | FBD Biologics Limited | 500 | 2025-03-13 | 2026-02-04 |
| A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors AK138D1 - Solid Cancer | Phase 1 | Recruiting | Akeso | 100 | 2025-02-24 | 2025-03-06 |
| Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients Blood sampling for pharmacokinetics - Solid Cancer, Gastric (Cardia, Body) Cancer | Recruiting | Erasmus Medical Center | 66 | 2025-02-18 | 2025-08-11 | |
| Study of Radiology Manipulator Work Validation by the Radiologist Solid Cancer | Recruiting | Institut Paoli-Calmettes | 87 | 2024-12-12 | 2025-03-25 | |
| A Study of HS-20124 in Patients with Advanced Solid Tumors HS-20124 (Phase Ia：Dose escalation ), HS-20124 (Phase Ib: Dose expansion) - Solid Cancer | Phase 1 | Recruiting | Hansoh BioMedical R&D Company | 450 | 2024-10-30 | 2025-01-08 |
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer R-DXd, Paclitaxel, Topotecan - Solid Cancer | Phase 2 / Phase 3 | Recruiting | Daiichi Sankyo | 860 | 2024-02-27 | 2026-10-26 |
| An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours LM103 - Solid Cancer | Early Phase 1 | Recruiting | Suzhou BlueHorse Therapeutics Co., Ltd. | 10 | 2024-01-23 | 2024-11-20 |
| Randomized Phase II Study to Evaluate Efficacy of Web-based Patient-reported Outcome (PRO) Application in Solid Cancer Patients Mobile PRO, usual care - Solid Cancer | Not applicable | Completed | Asan Medical Center | 166 | 2021-02-04 | 2025-12-24 |
| A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed BAY73-4506 (Regorafenib, Stivarga) - Solid Cancer | Phase 2 | Completed | Bayer | 6 | 2019-04-02 | 2024-04-02 |
| Metaxa Hospital THromboprophylaxis Program in Oncological & Surgical Patients Low Molecular Weight Heparin - Thrombosis, Solid Cancer | Unknown | Metaxa Hospital | 600 | 2018-12-01 | 2020-01-30 | |
| Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months - Solid Cancer | Phase 1 / Phase 2 | Terminated | Oncovir, Inc. | 7 | 2018-09-25 | 2021-02-01 |
Showing 20 of 25. Sign in to see all of them.
Neoplasms (4) · Colorectal Neoplasms (3) · Lymphopenia (2) · Melanoma (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Esophageal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Hand-Foot Syndrome (1) · Hematologic Neoplasms (1) · Ovarian Neoplasms (1) · Thrombosis (1) · Urologic Neoplasms (1)
Neoplasms by Site (7) · Neoplasms (5) · Colonic Diseases (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3) · Neoplasms by Histologic Type (3) · Rectal Diseases (3)
Cyclophosphamide (2) · Paclitaxel (2) · atezolizumab (2) · fludarabine (2) · pembrolizumab (2) · 1-dodecylpyridoxal (1) · 3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Blood Specimen Collection (1) · Bronchoscopes (1) · Capecitabine (1) · Carboplatin (1) · Cetuximab (1) · Etoposide (1)
Second Affiliated Hospital of Soochow University (3) · Akeso (2) · Asan Medical Center (1) · Assistance Publique - Hôpitaux de Paris (1) · Assistance Publique Hopitaux De Marseille (1) · BGI, China (1) · Bayer (1) · Beijing GoBroad Hospital (1) · Daiichi Sankyo (1) · Erasmus Medical Center (1) · FBD Biologics Limited (1) · Goethe University (1) · Hansoh BioMedical R&D Company (1) · Institut Claudius Regaud (1) · Institut Paoli-Calmettes (1)
China (10) · France (5) · United States (5) · Germany (3) · Australia (2) · Greece (2) · Italy (2) · Japan (2) · South Korea (2) · United Kingdom (2) · Brazil (1) · Canada (1) · Czechia (1) · Finland (1) · Netherlands (1)
David H Smith, MD (1) · Fabian Acker, MD (1) · Frederick P Smith, MD (1) · Nikos Ziras, MD (1) · Nina Bhardwaj, MD, PhD (1) · Sasan Karimi, MD (1) · Spyridon Xynogalos, MD (1) · Wenting Li, MD (1) · Xiao Sh Zhang, Doctor (1)
PMID 14639532, PMID 20697067, PMID 22065672, PMID 24812403, PMID 25117475, PMID 25837513, PMID 27312342, PMID 32889525, PMID 35552827, PMID 36306481, PMID 37301885, PMID 39142494, PMID 40767026, PMID 42109657, PMID 42864377
2018 (1)